• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

HYPITAT-II Childhood Neurodevelopmental Outcomes: Delivery or Expectant Management for Non-Severe Late Preterm Hypertension?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • HYPITAT-II trial (Hypertension and Preeclampsia Intervention Trial at near Term) studied whether immediate delivery or expectant management was preferable in women with mild late preterm hypertensive disorders of pregnancy (see ‘Related ObG Topics’ below)
    • There was no statistical risk reduction in adverse maternal outcomes in women who were delivered immediately (1.1%) compared to expectant management (3.1%)
    • There was a statistically significant increase in neonatal RDS in the immediate delivery group (5.7%) compared to the expectant management group (1.7%)
  • Zwertbroek et al. (AJOG, 2019) studied the effects of immediate delivery vs expectant management on the neurodevelopmental and behavioral outcomes at 2 years of those offspring whose mothers were enrolled in HYPITAT-II

METHODS:

  • Follow-up study of the HYPITAT-II trial, a randomized controlled trial (RCT)
    • HYPITAT-II trial: Women with hypertension between 34 and 37 weeks’ gestation were randomized to (1) immediate delivery vs (2) expectant monitoring
  • Participants in current study
    • Children born to women enrolled in HYPITAT-II
  • Data collection
    • Women were asked to complete the following when their toddlers were 2 years old
      • The Ages and Stages Questionnaire for developmental outcome (screening questionnaire for developmental delay)
      • The Child Behavior Checklist for behavioral problems (assesses behavioral and emotional issues)
    • Filled out between 23 and 26 months of age, corrected for prematurity

RESULTS:

  • 330 women returned the questionnaires | 61% of those approached
  • More children had an abnormal Ages and Stages Questionnaire score in the immediate delivery group
    • Immediate delivery group: 28% (45/162)
    • Expectant monitoring group: 18% (27/148)
    • Risk difference 9.6% (95% CI, 0.3 to 18.0%; P = .045)
    • Risk difference after correcting for maternal education: OR 0.48 (95% CI, 0.24 to 0.96; P = .03)
    • Most pronounces area of delay was that of fine motor skills
  • There was no statistical difference in the Abnormal Ages and Stage Questionnaire scores when comparing children born before or after 36 weeks
    • <36 weeks: 27%
    • >36 weeks: 22%
    • Odds ratio (OR) 0.77 (95% CI, 0.44 to 1.34)
  • There was no statistical difference found in the Abnormal Child Behavior Checklist
    • Immediate delivery group: 18% (31/175)
    • Expectant monitoring group: 15% (24/166)
    • Risk difference 3.2% (95% CI, –4.6% to 11.0%)

CONCLUSION:

  • Management strategy directly influenced gestational age at delivery, which together affect development
  • There may be an increased risk of developmental delay following early delivery, compared to expectant monitoring for women with late preterm hypertensive disorders of pregnancy
  • The authors state that

This follow-up study underlines the conclusion of the original HYPITAT-II study that, until the clinical situation deteriorates, expectant monitoring remains the most appropriate management strategy in the light of short- and long-term neonatal outcomes in women with preterm hypertensive disorders 

Learn More – Primary Sources:

Neonatal developmental and behavioral outcomes of immediate delivery versus expectant monitoring in mild hypertensive disorders of pregnancy: 2-year outcomes of the HYPITAT-II trial

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

HYPITAT-II: Immediate Delivery or Expectant Management for Non-Severe Hypertension at 34 – 37 weeks?
Diagnosing Preeclampsia – Key Definitions and ACOG Guidelines
ACOG Preeclampsia Guidelines: Antenatal Management and Timing of Delivery

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site